{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-029564","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.877615+00:00","generated_at":"2026-06-01T02:26:31.198845+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option","bullets":["Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.","Compensation includes $465K base salary, up to 40% target bonus, $50K sign-on cash award (12-month clawback).","Inducement option to purchase 150,000 shares vesting over 4 years (1-year cliff); exercise price set at June 24 close.","Varki previously US General Counsel at Idorsia, SVP/GC at Braeburn/Egalet, and 12 years at GSK.","Severance: 9 months salary (12 on change in control), pro-rated bonus, accelerated option vesting, 12 months COBRA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-029564","json":"https://secwatch.observer/filing/0001628280-24-029564.json","markdown":"https://secwatch.observer/filing/0001628280-24-029564.md","text":"https://secwatch.observer/filing/0001628280-24-029564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/0001628280-24-029564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/avtx-20240624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:26:31.198845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2daeb6d0ef","claim":"Paul Varki was appointed as Chief Legal Officer at Avalo Therapeutics, Inc..","evidence_excerpt":"On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/0001628280-24-029564-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Legal Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}